💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010

By FDA, JPN

💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application

Kyowa Hakko Kirin News

http://www.kyowa-kirin.com/news_releases/2017/pdf/e20171010_01.pdf

More from tokioX :

  1. Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
  2. 💊Pharma – News Releases
  3. 💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA
  4. 🚀JAXA | Successful Launch, H-IIA Launch Vehicle No. 36 Encapsulating MICHIBIKI No. 4  20171010
  5. ⚙Fujitsu to Conduct Blockchain Field Trial of Money Transfer Service with Three Major Japanese Banks – Fujitsu Global–   20171010
  6. 💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)
  7. PDF]US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome  Kyowa Hakko Kirin News Releases